The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Neogen (NEOG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

PRGO vs. NEOG: Which Stock Is the Better Value Option?

Food Safety segment drives 4.3% core growth as company executes transformation strategy.

How Neogen’s latest earnings report is shaping the stock story Neogen (NEOG) has just reported fourth quarter and full year results to May 31, 2026, alongside fresh revenue guidance for fiscal 2027. This combination of backward looking figures and management expectations is now in focus for investors. For the fourth quarter, Neogen reported revenue of US$225.3 million compared with US$225.5 million a year earlier. The company recorded a net loss of US$11.3 million, while the prior year...

Neogen Corporation recently reported fiscal fourth-quarter and full-year 2026 results, posting Q4 revenue of US$225.3 million with a US$11.3 million net loss, and issued fiscal 2027 revenue guidance of US$880 million to US$885 million alongside plans for increased R&D and transformation spending. Despite full-year revenue easing to US$870.4 million and a US$7.9 million annual net loss, Neogen sharply reduced losses from the prior year while boosting core revenue growth and outlining plans to...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Neogen Corp (NEOG) reports a 7% year-over-year revenue increase in Q4, driven by food safety and animal health demand, while navigating foreign exchange pressures and supply chain disruptions.

The headline numbers for Neogen (NEOG) give insight into how the company performed in the quarter ended May 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Life sciences company Neogen (NASDAQ:NEOG) reported Q2 CY2026 results topping the market’s revenue expectations, but sales were flat year on year at $225.3 million. The company’s full-year revenue guidance of $882.5 million at the midpoint came in 3.9% above analysts’ estimates. Its non-GAAP profit of $0.09 per share was 58.8% above analysts’ consensus estimates.

Neogen (NASDAQ:NEOG) reported fiscal fourth-quarter revenue of $225.3 million, with core revenue growth of 4.3%, its highest growth rate of fiscal 2026. The company said momentum improved across both its food safety and animal safety businesses as it entered fiscal 2027, while management outlined in

Neogen (NEOG) delivered earnings and revenue surprises of +80.00% and +6.29%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

Life sciences company Neogen (NASDAQ:NEOG) will be reporting earnings this Thursday morning. Here’s what to expect.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.